Carvedilol
| Evidence Level: L5 | Predicted Indications: 4 |
Table of Contents
Carvedilol: Malignant hypertensive renal disease
One-Sentence Summary
Carvedilol is a marketed beta-blocker with alpha-1 blocking activity, originally used to treat hypertension. The TxGNN model predicts it may be effective for malignant hypertensive renal disease, but no clinical trials and no publications specific to this indication were found, so the prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Malignant hypertensive renal disease |
| TxGNN Prediction Score | 0.9955 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, carvedilol is a non-selective beta-blocker with additional alpha-1 blockade. Its efficacy in hypertension is established, and mechanistically it may be applicable to severe hypertension with kidney involvement through blood pressure lowering and reduced renin release.
The new indication is very close to the original one. Malignant hypertensive renal disease is a severe, kidney-damaging form of hypertension, so the high score may largely reflect proximity to the existing hypertension label rather than a genuinely new repurposing signal. In clinical practice, malignant hypertension is usually managed with rapid-acting parenteral agents, so the role of an oral beta-blocker is uncertain and cannot be verified from the available data.
The same model also ranks other related predictions: malignant renovascular hypertension (0.9955, also L5, no trials or literature), two forms of pulmonary hypertension (0.9954), and Braddock syndrome (0.9937, no identifiable mechanistic link). Among these, the pulmonary hypertension entry linked to lung disease and/or hypoxia has the only retrieved literature (indirect, mostly preclinical, L4). It includes a rat study showing carvedilol reversed hypertension induced by chronic intermittent hypoxia (PMID 26291659) and a rat study showing adrenergic blockade reversed right heart remodeling in pulmonary hypertension (PMID 20508210). Beta-blockade in lung disease and pulmonary arterial hypertension carries safety concerns.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for malignant hypertensive renal disease.
India Market Information
Carvedilol is marketed in India with 20 valid single-ingredient registrations. Approved indication text was not available for these products. Five examples:
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 118712 | Kar-B 6.25mg Tablet (J B Chemicals and Pharmaceuticals) | Tablet (strip of 10) | Not available |
| 40998 | Carvipress 25mg Tablet (Micro Labs) | Tablet (strip of 10) | Not available |
| 45513 | Carveford 12.5mg Tablet (Leeford Healthcare) | Tablet (strip of 10) | Not available |
| 45707 | Cvdol-CR 10 Tablet (Care Formulation Labs) | Controlled-release tablet (strip of 10) | Not available |
| 35923 | Cardivas CR 40 Tablet (Sun Pharmaceutical) | Extended-release tablet (strip of 10) | Not available |
All products are oral tablets (immediate-release, controlled-release, and extended-release).
Safety Considerations
- Contraindications (not label text): liver failure, asthma (including intrinsic and allergic), bronchitis, pulmonary emphysema and other bronchial disease, diabetes mellitus, diabetic ketoacidosis, hypotensive disorder, peripheral vascular disease (including intermittent claudication and peripheral arterial disease), atrioventricular block, sick sinus syndrome (including the familial form), Prinzmetal angina, anaphylaxis, intraoperative floppy iris syndrome.
- Drug Interactions: 329 interactions were recorded. The main one is Epinephrine (Major). Moderate interactions include corticosteroids (hydrocortisone, dexamethasone, betamethasone, triamcinolone, budesonide), bupropion, morphine, atropine, hyoscyamine, lorcaserin, canagliflozin, acetohexamide, and calcium salts (phosphate, acetate, carbonate, citrate). Minor interactions include acetylsalicylic acid, aluminum hydroxide, and attapulgite.
- For pulmonary hypertension in particular, the non-selective beta-blockade raises a theoretical bronchospasm concern in lung disease and hypoxia.
Please also refer to the package insert for label warnings, which were not available for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a high model score but no clinical trials or literature for this indication (Evidence Level L5). The new indication overlaps heavily with the existing hypertension use, and standard management of malignant hypertension relies on parenteral agents.
To proceed, the following is needed:
- Mechanism of action data (MOA) to support the mechanistic link
- Package insert warnings and contraindications from the Indian regulator, which are currently missing and block safety screening
- Indication-specific clinical or observational evidence for malignant hypertensive renal disease
- A safety review of the knowledge-graph contraindications, especially bronchospastic disease, diabetes, hypotension, and conduction disorders
- If the pulmonary hypertension predictions are pursued, dedicated preclinical and clinical evidence addressing beta-blocker safety in that setting
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.